GDS Wealth Management Takes $240,000 Position in Eli Lilly and Company (NYSE:LLY)

GDS Wealth Management acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 265 shares of the company’s stock, valued at approximately $240,000.

Several other large investors have also bought and sold shares of LLY. Lynx Investment Advisory bought a new stake in shares of Eli Lilly and Company during the second quarter worth about $32,000. LGT Financial Advisors LLC acquired a new stake in Eli Lilly and Company in the second quarter valued at $36,000. Morton Brown Family Wealth LLC increased its stake in shares of Eli Lilly and Company by 45.5% in the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after buying an additional 15 shares during the period. Core Wealth Advisors Inc. raised its holdings in Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares during the last quarter. Finally, Tidemark LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $29,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 9,671 shares of the business’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $902.67, for a total transaction of $8,729,721.57. Following the transaction, the insider now directly owns 97,574,139 shares in the company, valued at $88,077,248,051.13. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 451,900 shares of company stock worth $418,732,178 over the last quarter. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 0.0 %

Shares of NYSE LLY opened at $924.05 on Tuesday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a 1 year low of $516.57 and a 1 year high of $972.53. The stock has a market capitalization of $878.22 billion, a P/E ratio of 136.09, a P/E/G ratio of 2.79 and a beta of 0.42. The company has a 50-day moving average price of $897.24 and a 200-day moving average price of $835.09.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. On average, equities research analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were paid a $1.30 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.56%. Eli Lilly and Company’s payout ratio is 76.58%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Morgan Stanley reissued an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Citigroup started coverage on Eli Lilly and Company in a research report on Friday. They issued a “buy” rating and a $1,060.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday. Berenberg Bank raised their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Finally, BMO Capital Markets boosted their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.